Miraculins on Tuesday announced that it will be commencing a pilot program with Lovell Drugs and Pear Healthcare Solutions that will see the placement of the first stand-alone, Scout DS diabetes screening kiosks in Lovell’s retail pharmacy locations in Ontario.
Rep. Jason Chaffetz, R-Utah, last week introduced a bill that would extend to new combination drugs containing molecules already approved by the Food and Drug Administration the same five-year market exclusivity as a drug product containing an entirely new set of active ingredients.
HIV patients using a mobile app — which can provide refill reminders, dosage reminders and other prescription management functionality — are 2.9 times more likely to be adherent.
Health and Human Services Secretary Sylvia Burwell on Monday announced measurable goals and a timeline to move the Medicare program, and the healthcare system at large, toward paying providers based on the quality of care they give patients.
Teva Pharmaceutical Industries announced that the Food and Drug Administration approved the company’s first generic Nexium delayed-release tablets in the United States.
The Food and Drug Administration on Monday announced approval for the first generic version of Nexium (esomeprazole magnesium delayed-release capsules), which are used to treat gastroesophageal reflux disease in adults and children ages 1 year and older.
Will patient screenings and advanced, gene-based diagnostics become a standard and universally accepted part of community pharmacy’s service platform?
The Food and Drug Administration last week announced approval for Bexsero, a vaccine intended to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 years through 25 years of age.
The Food and Drug Administration last week approved Natpara (parathyroid horomone), which is indicated to control low blood calcium levels in patients who have hypoparathyroidism.
Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.